Journal Watch · eLife · 2026
Uev1A counteracts oncogenic <i>Ras</i> stimuli in both polyploid and diploid cells.
Remarkably, elevated expression levels of UBE2V1/2 correlate with improved survival rates in human colorectal cancer patients harboring oncogenic <i>KRAS</i> mutations, indicating that their upregulation could represent a promising therapeutic strategy.
TL;DR
Remarkably, elevated expression levels of UBE2V1/2 correlate with improved survival rates in human colorectal cancer patients harboring oncogenic <i>KRAS</i> mutations, indicating that their upregulation could represent a promising therapeutic strategy.
Key findings
- Although Uev1A is primarily known for its non-proteolytic functions, our studies demonstrate that it collaborates with the E3 APC/C complex to mediate the proteasomal degradation of Cyclin A, a key cyclin that drives cell division.
- Furthermore, Uev1A and UBE2V1/2 also counteract oncogenic <i>Ras</i>-driven tumorigenesis in diploid cells, suppressing the overgrowth of germline tumors in <i>Drosophila</i> and human colorectal tumor xenografts in nude mice, respectively.
- Remarkably, elevated expression levels of UBE2V1/2 correlate with improved survival rates in human colorectal cancer patients harboring oncogenic <i>KRAS</i> mutations, indicating that their upregulation could represent a promising therapeutic strategy.
What they did
To explore intrinsic protective mechanisms against this specific form of cellular stress, here, we conducted a genome-wide genetic screen and identified the E2 enzyme Uev1A as a key protector. Reducing its expression levels exacerbates the nurse cell death induced by oncogenic <i>Ras</i>, while overexpressing it or its human homologs, UBE2V1 and UBE2V2, mitigates this effect.
Full abstract (original)
Background: Oncogenic <i>Ras</i> is known to induce DNA replication stress, leading to cellular senescence or death. In contrast, we found that it can also trigger polyploid <i>Drosophila</i> ovarian nurse cells to die by inducing aberrant division stress.
What they did: To explore intrinsic protective mechanisms against this specific form of cellular stress, here, we conducted a genome-wide genetic screen and identified the E2 enzyme Uev1A as a key protector. Reducing its expression levels exacerbates the nurse cell death induced by oncogenic <i>Ras</i>, while overexpressing it or its human homologs, UBE2V1 and UBE2V2, mitigates this effect.
Results & conclusions: Although Uev1A is primarily known for its non-proteolytic functions, our studies demonstrate that it collaborates with the E3 APC/C complex to mediate the proteasomal degradation of Cyclin A, a key cyclin that drives cell division. Furthermore, Uev1A and UBE2V1/2 also counteract oncogenic <i>Ras</i>-driven tumorigenesis in diploid cells, suppressing the overgrowth of germline tumors in <i>Drosophila</i> and human colorectal tumor xenografts in nude mice, respectively. Remarkably, elevated expression levels of UBE2V1/2 correlate with improved survival rates in human colorectal cancer patients harboring oncogenic <i>KRAS</i> mutations, indicating that their upregulation could represent a promising therapeutic strategy.
Abstract © the authors / eLife (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.7554/elife.107104 · PubMed 41879050.
Why it matters for pharma & biotech
- Directly relevant to teams in targeted oncology / immuno-oncology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: targeted oncology / immuno-oncology
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this eLife study find?
Remarkably, elevated expression levels of UBE2V1/2 correlate with improved survival rates in human colorectal cancer patients harboring oncogenic <i>KRAS</i> mutations, indicating that their upregulation could represent a promising therapeutic strategy.
What type of study is this?
It is a preclinical (animal / model) study, published in eLife in 2026. To explore intrinsic protective mechanisms against this specific form of cellular stress, here, we conducted a genome-wide genetic screen and identified the E2 enzyme Uev1A as a key protector.
Where can I read the original paper?
The original is at the publisher via DOI 10.7554/elife.107104. PubMed ID: 41879050. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/uev1a-counteracts-oncogenic-lt-i-gt-ras-lt-i-gt-stimuli-in-both-polyploi-107104/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides